What's Happening?
The American Cancer Society has updated its guidelines to include a blood test as a screening option for colorectal cancer. This new recommendation aims to provide an alternative for adults aged 45 and older who are at average risk and have declined traditional
visual or stool-based tests. The Shield test, developed by Guardant Health and approved by the FDA in 2024, detects tumor DNA in the blood with 83% sensitivity for colorectal cancer. However, it is less effective at identifying precancerous polyps. The inclusion of blood testing is intended to increase screening rates, as colorectal cancer has become the leading cancer killer among U.S. adults under 50.
Why It's Important?
The addition of a blood test to colorectal cancer screening options is significant as it addresses the gap in screening participation. Many individuals avoid traditional screening methods due to their invasive nature or the discomfort of stool collection. By offering a less invasive option, the American Cancer Society hopes to increase early detection rates, which can dramatically improve survival outcomes. Early detection allows for timely treatment, potentially reducing the mortality rate associated with colorectal cancer. This development could lead to broader acceptance and utilization of cancer screening, ultimately improving public health outcomes.
What's Next?
The American Cancer Society's updated guidelines may influence future screening practices and insurance coverage policies. As the Shield test gains acceptance, other blood-based tests may emerge, further expanding screening options. The U.S. Preventive Services Task Force, which guides insurance coverage, may consider incorporating blood testing into its recommendations. Additionally, ongoing research may lead to further advancements in screening technologies, potentially lowering the recommended screening age. Healthcare providers and policymakers will need to evaluate the effectiveness and cost implications of these new screening methods to ensure they are accessible and beneficial to the population.
